Oncological issues of hormonal contraception and hormone replacement therapy

Abstract

The article gives critical analysis of numerous epidemiological studies touching upon the problems of carcinogenesis while using hormonal contraception and hormonal replacement therapy and also the expediency of HRT as to oncologic patients after radical treatment.
The materials presented testify to relative carcinogenous safety of hormonal contraceptives as to the majority of tumors and even considerable decrease of endometrial and ovarian cancer risk; but some investigations point to the increase о f breast cancer in case о f prolonged application о f hormonal preparations.
The results оf the analysis show that HR Tmay be recommended among female population providing active screening, especially of mammary glands and endometrium. Besides that, hormonal preparations are not excluded for rehabilitation of some oncologic patients underthorough monitoring. Yet, there exists burning necessity of continuing cooperated scientific and clinical investigations forfurther studying oncologic aspects of hormonal contraception and HRT.

Keywords

cancer risk / hormonal contraception / radical treatment

References

[1] Урманчеева А. Ф., Берштейн Л. М., Бурмина М. М. и др.

[2] Гэрмональная реабилитация больных раком шейки матки после радикального хирургического лечения // Журн. акуш. и жен. болезней. — 2001. — Вып. 1. — Т. XLIX. - С. 58-62.

[3] Adami Н. -О., Persson I., Hoover В., etal. //1 nt. J. Cancer. — 1989. - Vol. 44. - P. 833-839.

[4] BeralV, Hermon C., KayC., etal. //Br. med. J. - 1999. - Vol. 318. - P. 96-100.

[5] Brinton L. A., Hoover R. N., et al. // Obstet. Gynecol. — 1993. — Vol. 81.- P. 265-271.

[6] Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. //New Engl. J. Med.— 1987. - Vol. 316. -P. 650-655.

[7] Chapman J. A., Di Saia P, OsannK., etal. //Amer. J. Obstet. Gynecol. - 1996. - Vol. 175. - P. 1195-2000.

[8] ChowW.-H., McLaughlin J. K., Mandel J. S., etal. // Int. J. Cancer.— 1995. — Vol. 60. — P. 321-324.

[9] Collaborative Group on Hormonal Factors in Breast Cancer. // Lancet.- 1996. - Vol. 347. - P. 1713-1727.

[10] Collaborative Group on Hormonal Factors in Breast Cancer. // Lancet.- 1997. - Vol. 350. - P. 1047-1059.

[11] Collaborative MILTS Project Team. //Contraception. — 1997. — Vol. 56. - P. 275-284.

[12] EelesR.A., TanS., WiltshawE., etal.//Brit. Med. J. - 1991. - Vol. 303. - P. 259.

[13] Ettinger B., Selby J., Citron J. T., et al. // Obstet. Gynecol. — 1994. — Vol. 83. - P. 693-700.

[14] Fathalla M.F. //Lancet. — 1971. - Vol. /7. - P. 163.

[15] Fernandez E., La VecchiaC., Franceschi S., et al. // Epidemiology. — 1998. — Vol. 9. — P. 295-300.

[16] Forman D., Doll R., Peto R. // Br. J. Cancer. - 1983. - Vol. 48. - P. 349-354.

[17] Franceschi S., Bidoli E., TalaminiR., etal. //Eur. J. Cancer.- 1991. - Vol. 27. - P. 604-608.

[18] Gambrell R. D. // Maturitas. — 1986. - Vol. 8. - P. 159-168.

[19] Grady D., Gebretsadik T, Kerlikowske K., et al. // Obstet. Gynecol. - 1995. - Vol. 85. - P. 304-313.

[20] Grodstein F., StampferM. J., Colditz G. A., et al. // New Engl. J. Med. — 1997. — Vol. 336. - P. 1769-1775.

[21] Guidozzi F, Paponte A. //Inter. J. Gynecol. Cancer. — 1999. — Vol. 9. - P. 5.

[22] Hammond С. B., Jelovsek F. R., Lee K. L., etal. //Am. J. Obstet. Gynecol. - 1979. - Vol. 133. - P. 537-547.

[23] Harris R., Whittemore A. S., Itnyre J. & the Collaborative Ovarian Cancer Group. //Am. J. Epidemiol. - 1992. - Vol. 136. - P. 1204-1211.

[24] Henderson В. E., Paganini-Hill A., Ross R. K. //Arch. Intern. Med. — 1991. - Vol. 151. - P. 75-78.

[25] Horn-Ross P. L., Whittemore A. S., Harris R., Itnyre J. & the Collaborative Ovarian Cancer Group. // Epidemiol. — 1992. — Vol. 3. - P. 490-495.

[26] Hulka B. S., Chambless L. E., Kaufman D. G., et al. //J. Am. med. Assoc. - 1982. - Vol. 247. - P. 475-477.

[27] IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans — Lyon, 1979. — Vol. 21: Sex Hormones (II).

[28] IARC monographs on the evaluation of carcinogenic risks to humans. — Lyon, 1999. — Vol. 72: Hormonal contraception and postmenopausal hormonal therapy.

[29] La VecchiaC., Negri E., Levi R, etal.//Eur. J. Cancer. — 1998. — Vol. 34. - P. 118-141.

[30] MantJ. W. F, VesseyM. P. // Вr. J. Cancer. — 1995. — Vol. 72. — P. 800-803.

[31] Nachtigall L. E., Nachtigall R. H., Nachtigall R. D., et al. // Obstet.Gynecol. — 1979. — Vol. 53. — P. 277-281.

[32] NarodS.A., RischH., MoslehiR., et al. // New Engl. J. Med. - 1998. - Vol. 339. - P. 424-428.

[33] Olsson H., Moller T. R., Ranstam J. // J. Natl. Cancer Inst. — 1989. - Vol. 81.- P. 1000-1004.

[34] ParazziniE., La VecchiaC., NegriE., etal. //Вr. J. Cancer. — 1995. - Vol. 71.- P. 644-646.

[35] Persson I., Adami H. 0., BergkvistL., etal. //Br. med. J. — 1989. - Vol. 298. - P. 147-151.

[36] Persson I., Schmidt M., Adami H. O., et al. // Cancer Causes Control. - 1990. - Vol. 1. - P. 201-208.

[37] Persson I., Yuen J., BergkvistL. etal. //Int. J. Cancer. — 1996. — Vol. 67. - P. 327-332.

[38] PowlesT. P., CaseyS., O’Brien M., etal. //Lancet. — 1993. - Vol. 42. - P. 60-61.

[39] Risch H. A., MarrettL. D., Jain M., etal. //Am. J. Epidemiol. — 1996. - Vol. 144. - P. 363-372.

[40] Rosenblatt K. A., Thomas D. B. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. //Int. J. Cancer. — 1991. - Vol. 49. - P. 870-874.

[41] Rosenblatt K. A., Thomas D. B., Noonan E. A. & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives. //Eur. J. Cancer. - 1992. - Vol. 28A, P. 1872-1876.

[42] SurianoK., McHale M., Re A., etal. //Inter. J. Gynec. Cancer. — 1999 - Vol. 9. - P. 83.

[43] Thomas D. B., RayR. M. & the WHO Collaborative Study of Neoplasia and Steroid Contracaptives // Contraception. — 1995. - Vol. 52. - P. 307-312.

[44] Ursin G., Hendersen В. E., Haile R. W., et al. // Cancer Res. — 1997. - Vol. 57. - P. 3678-3681.

[45] Voigt L. F., DengQ., Weiss N. S. R// Cancer Causes Control. — 1994. - Vol. 5. - P. 227-233.

[46] Waetjen L. E., Grimes D. A. // Obstet. Gynecol. — 1996. — Vol. 88. - P. 945-949.

[47] Weiss N. S., Lyon J. L., KrishnamurthyS., etal.//J. Natl. Cancer Inst. — 1982. — Vol. 68. — P. 95-98.

[48] WHO Collaborative Study of Neoplasia and SteroidContraceptives. //Int. J. Epidemiol.- 1988. - Vol. 17. - P. 263-269.

[49] WHO Collaborative Study of Neoplasia and Steroid Contraceptives // Int. J. Cancer. - 1991. - Vol. 49. - P. 182-185

RIGHTS & PERMISSIONS

Eсо-Vector